DYN 250117 35.00C (DYN250117C35000) Stock Options, News & Quotes

US OptionsDetailed Quotes

DYN250117C35000

Watchlist

1.81
+1.76+3520.00%

15min DelayClose Jan 17 16:00 ET

1.81High1.81Low

Intraday

5D
Daily

News

Dyne Therapeutics To Present At J.P. Morgan Healthcare Conference; Webcast At 1:30 PM ET
RTTNewsJan 15 12:31 ET
Positive Outlook for Dyne Therapeutics as DYN-101 Shows Promising Clinical Results and Strategic Regulatory Advancements
TipRanksJan 11 10:39 ET
Dyne Therapeutics: Positive Phase 1/2 Trial Results for DYNE-101 Lead to Buy Rating and Overweight Stock Recommendation
TipRanksJan 11 10:37 ET · Ratings
Small U.S. Stocks Close Lower; Dyne Therapeutics Posts Biggest Loss
Dow JonesJan 10 16:20 ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
BenzingaJan 10 16:06 ET
Dyne Therapeutics Is Maintained at Buy by Chardan Capital
Dow JonesJan 10 14:36 ET · Ratings

Comments

Spinee

Jul 15, 2024 02:41

XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details

These ten mid-cap stocks were the best performers in the last week. Are they in your portfolio?
$XPeng (XPEV.US)$ stock rose 15.56%. Shares of Chinese stocks gained following an increase in China's June exports.
$QuantumScape (QS.US)$ stock jumped 64.34% after the company announced it entered into an agreement with Volkswagen $VOLKSWAGEN A G (VWAGY.US)$ 's battery company PowerC...

Trytosaveabit

May 20, 2024 12:31

$Dyne Therapeutics (DYN.US)$ Looking like a nice market response to the news/update

Trytosaveabit

May 20, 2024 05:42

News

$Dyne Therapeutics (DYN.US)$ Dyne Therapeutics Announces New Clinical Data From ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints
GlobeNewswire· 7 mins ago
- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 Months -
- DYNE-101 Showed Improvement in Myotonia, Muscle Strength, ...

Meltyy

May 16, 2024 01:19

🔔 RA Capital Q1 ‘24* Holdings Released... 🐳

» Holdings: 75
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S (ASND.US)$
$Vaxcyte (PCVX.US)$
$Legend Biotech (LEGN.US)$
$Janux Therapeutics (JANX.US)$
$Aerovate (AVTE.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Evolent Health (EVH.US)$
$NewAmsterdam Pharma (NAMS.US)$
$RxSight (RXST.US)$
$TYRA BIOSCIENCES, INC. (TYRA.US)$
$Edgewise Therapeutics (EWTX.US)$
$4D Molecular Therapeutics (FDMT.US)$
$Biogen (BIIB.US)$
$PepGen (PEPG.US)$
...

Moomoo AI

Mar 25, 2024 06:38

John Cox's appointment, with his vast biotech industry and rare disease commercialization experience, is viewed positively for Dyne Therapeutics. His leadership is anticipated to enhance the company's clinical programs and pipeline, and build more capabilities as Dyne continues to create stakeholder value.

Press Release: Dyne Therapeutics Announces CEO Transition